SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus upcoming oncology milestones are driving attention, particularly the completed IMPACT pancreatic-cancer trial enrollment and expected data, alongside further REGAIN glioblastoma updates. Traders are broadly optimistic about the expanding pipeline, while some emphasize that larger datasets are still needed to validate the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are watching a governance vote that could make NEAR less inflationary, with some viewing the tokenomics change as a potential catalyst. Sentiment is split: dip-buyers are accumulating, while cautious traders point to Bitcoin-linked weakness and liquidation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Discussion centers on frustration over delayed PF614-MPAR and CY200 updates and uncertainty about Nasdaq compliance and a possible reverse split, alongside distrust of management and dilution concerns, while some investors remain hopeful about the funded pipeline and upcoming clinical milestones.

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million.
Ensysce Biosciences (NASDAQ:ENSC) stock roseread more...

Catalysts Put These Companies in the Spotlight

ClearOne (NASDAQ CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.

Ensysce Lands Up to $77 Million to Fuel Next Generation Pain Therapy Pipeline

Ensysce Biosciences (NASDAQ: ENSC) has taken a significant strategic step toward becoming a broader pain therapeutics company with the acquisition of clinical-stage Cy Biopharma, bringing together two distinct approaches to addressing one of healthcare's largest unmet needs. The transaction is backed by up to $77 million in financing and positions the combined company to advance both a next-generation non-opioid pain therapy and Ensysce's proprietary abuse-resistant opioid platform.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million.
Adagio Medical Holdings (NASDAQ:ADGM) stockread more...

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million.
TransCode Therapeutics (NASDAQ:RNAZ)read more...

Top Penny Stocks To Follow Today - February 27th

OneMedNet, Ensysce Biosciences, and Banco Bradesco are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small companies that...

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review

Ensysce Biosciences stock surged 58% after launching a strategic review to explore partnerships, licensing deals, or asset sales.read more...

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

Equity

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

This account has been verified as an official ENSC representative.

Verified Account

Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Ensysce Biosciences Inc

Extremely Bearish Sentiment

Shares of Ensysce Biosciences, Inc. (ENSC) traded nearly 11% higher on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ensysce.com/news/press-releases/detail/186/ensysce-biosciences-announces-positive-data-from-opioid">said</a> its PF614-MPAR pain relief medication demonstrated in a study that it can deliver strong relief for severe pain while protecting from the risk of excessive doses.The company completed the first part of its second clinical trial to evaluate PF614-MPAR for overdose protection. It confirmed that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.CEO Bill Schmidt said that the clinical data demonstrates the ability of the company’s Multi-Pill Abuse Resistance (MPAR) platform as a vital tool to limit overdoses from prescription medications.Ensysce said that the maximum amount of oxycodone released from PF614-MPAR when three or more doses were taken at one time was reduced compared to that released following the consumption of the same amount of PF614 alone.The company said that the new data demonstrates overdose protection across the full dosage range of PF614-MPAR, which is planned for commercialization. It added that this analysis will be discussed with the U.S. Food and Drug Administration (FDA) in an upcoming meeting.The company will now continue to enroll for parts 2 and 3 of the clinical trial, which will allow it to perfect a final drug product for commercialization.On Stocktwits, retail sentiment around Ensysce Biosciences jumped nine points in the ‘extremely bullish’ territory while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:1300/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_1_11_30_PM_png_9a122ca00d.webp" alt="ENSC's Sentiment Meter and Message Volume as of 1:30 p.m. ET on April 14, 2025 | Source: Stocktwits" width="1300" height="298"><figcaption>ENSC's Sentiment Meter and Message Volume as of 1:30 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the shares rallying to $6 from their current $2 levels.<stembedurl>https://stocktwits.com/LowFloatSniper/message/611712896</stembedurl><a href="https://stocktwits.com/symbol/ENSC">ENSC stock</a> is down nearly 73% year-to-date and about 78% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/barclays-downgrades-us-auto-sector-owing-to-trump-tariffs/chQRkPFRbOT">Barclays Downgrades US Auto Sector Owing To Trump’s Tariffs: Retail Sentiment Around GM Takes A Plunge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.421
Prev Close	$0.438
Open	$0.435
Dividend Yield	0.00%
50-Day Moving Average	$0.452
Beta	1.20
Avg. Volume	502,807.81
PE Ratio	-0.15

52-Week High	$2.23
52-Week Low	$0.23
Market Capitalization	$8.52M
EPS (Annual)	-$3.98
Price to Book	-8.74
Revenue Per Employee	$506,665.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ENSC Fundamentals